Company · CIK 1885522
Neumora Therapeutics, Inc.
| CIK | 1885522 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2836 — Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
| Business address | MA |
| Listed | NMRA (Nasdaq) |
| First annual or quarterly report | 2023-11-01 |
Offerings
2 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-282460 | 2024-10-01 | 2025-03-26 | 2 | |
| 333-274229 | 2023-08-25 | 2023-09-18 | 4 |
Filings
7| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2025-03-26 | EFFECTDeclared effective | 333-282460 | 9999999995-25-000791 |
| 2024-10-01 | S-3ASRShelf registered | 333-282460 | 0001193125-24-230348 |
| 2023-09-18 | 424B4Final prospectus | 333-274229 | 0001193125-23-236920 |
| 2023-09-14 | EFFECTDeclared effective | 333-274229 | 9999999995-23-002676 |
| 2023-09-11 | S-1/AAmendment | 333-274229 | 0001193125-23-231902 |
| 2023-08-25 | S-1Registration filed | 333-274229 | 0001193125-23-221589 |
| 2021-11-08 | DRSDraft made public | 377-05663 | 0000950123-21-014224 |